dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada SGLT-2 inhibitors, agonists, inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study Clinical Use of DPP-4 Inhibitors

This activates multiple signaling pathways including protein kinase A/signal transducer and activator of transcription, phosphoinositide 3-kinases/protein kinase B, mitogen-activated protein kinase, and nuclear factor kappa B, and may exert anti-inflammatory effects in the liver and beyond

Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis

Br J Ophthalmol 96(3):375379 Group OCTS-SCfNIIHS et al (2014) Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features

FDA approval for indications in weight management

Foundayo will be the second oral GLP-1 drug available to consumers, after competitor Novo Nordisk introduced its Wegovy pill in January

Monami M., Dicembrini I., Nardini C., Fiordelli I., and Mannucci E., GlucagonLike Peptide1 Receptor Agonists and Pancreatitis: A MetaAnalysis of Randomized Clinical Trials, Diabetes Research and Clinical Practice 103 (2014): 269275